Recent News Releases

Marketing Authorization Application (MAA) for etranacogene dezaparvovec will be reviewed under accelerated assessment and has the potential to be the first gene therapy for patients living with...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 23 March 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 8 March 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 3 March 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology...

With 25,000 global employees, CSL is one of 500 Large Employers recognized across 25 industry sectors KING OF PRUSSIA, Pa., 2 March 2022 – Forbes Magazine has named global biotechnology leader...

Forbes Magazine has named global biotechnology leader CSL among America's Best Employers for 2022. The annual rankings from Forbes and Statista, the world-leading statistics portal and industry...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of...

• Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA) to strengthen preparedness and rapid response...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Net sales up 4.0% and EBITDA up 6.6% at constant exchange rates (CER) a result of profitable growth in net sales combined with diligent cost containment...

New facility in Waltham, Massachusetts, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform, the next generation of mRNA vaccine technology, for...